Shareholding pattern data is currently unavailable for this company. Please check back later.
There is currently no consolidated profit & loss data available for this company. Please switch to Standalone to view available financials.
There is currently no consolidated cash flow data available for this company. Please switch to Standalone to view available financials.
There is currently no consolidated quarterly financial results available for this company. Please switch to Standalone to view available financials.
There is currently no consolidated balance sheet data available for this company. Please switch to Standalone to view available financials.
Financial ratio data is currently unavailable for this company. Please check back later.
Investor''s presentation on unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026
The Board of Directors at its meeting held on October 27, 2026 has fixed Wednesday, November 04, 2026 as record date for issuance of Bonus equity shares in the ratio of 1:1.
Unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026.
The Board of Directors of the Company, at its meeting held today i.e. Tuesday, October 27, 2026, has inter-alia considered and approved the Un-audited financial results for the quarter and half year ended September 30, 2026, Record date for issue of Bonus equity shares and reconstituted committees of Board.
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026 along with Limited Review Report thereon
In compliance with regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate received from RTA of the Company.
We are pleased to announce the successful completion of inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit - II formulation facility.